Single-receptor incretin vs the leading triple-receptor next-generation molecule. What the early phase-2 retatrutide data actually shows.
Semaglutide is the most-studied single-receptor incretin agonist; retatrutide is the leading next-generation candidate, hitting three receptors at once. The phase-2 retatrutide data in NEJM is the headline reference here.
| Semaglutide | Retatrutide | |
|---|---|---|
| Class | GLP-1 agonist | Triple GLP-1 / GIP / glucagon agonist |
| Receptors activated | 1 | 3 |
| FDA status | Approved (multiple brands) | Investigational (Phase 3) |
| Half-life | ~7 days | ~6 days |
| Avg weight reduction (phase-2/3 trials) | ~15% (STEP 1, 68 wk) | ~24% at 48 wk (Phase 2) |
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is one of the most-studied incretin-class molecules and underpins several FDA-approved branded medications in clinical settings.
Semaglutide mimics endogenous GLP-1, stimulating glucose-dependent insulin secretion, slowing gastric emptying, and acting on central appetite-regulation pathways.
Retatrutide is a synthetic peptide engineered to activate three incretin/metabolic receptors at once — GLP-1, GIP, and glucagon. It is currently in late-stage clinical trials and represents the leading edge of next-generation metabolic peptide research.
Simultaneous agonism of GLP-1, GIP, and glucagon receptors combines incretin effects (insulin secretion, gastric emptying, appetite) with glucagon-driven energy expenditure.
Retatrutide's phase-2 numbers are the largest reported for any incretin-class molecule, but it is still investigational. Semaglutide remains the clinical baseline.
The table above compares published characteristics, not outcomes for any individual. Mechanism, half-life, and dosing cadence are properties of the molecule; response, tolerability, and suitability are properties of the person. Trial averages describe populations and say nothing definitive about a single case.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Semaglutide targets the GLP-1 receptor alone. Tirzepatide is a dual GIP/GLP-1 receptor agonist, hitting two incretin pathways at once.
Yes. Any clinical use must be directed by a licensed medical practitioner. Research-use product is supplied for investigational purposes only.
Retatrutide activates three receptors (GLP-1, GIP, glucagon) versus semaglutide's one and tirzepatide's two. The added glucagon arm is thought to increase energy expenditure.
No — as of 2026 it is investigational and in late-stage trials.